Back to search results

Study of JANX014 for Metastatic Castration-Resistant Prostate Cancer

This study is testing a new treatment called JANX014 for men with metastatic castration-resistant prostate cancer (mCRPC). This is a type of prostate cancer that has spread and no longer responds to standard hormone therapy. JANX014 is a type of CAR-T therapy, which uses your own immune cells to fight cancer. To join, you must be at least 18 years old, have confirmed prostate cancer, and your cancer must have progressed after certain previous treatments. The main goals of this study are to see how safe JANX014 is and what side effects it might cause. The study is currently open, and they plan to enroll 43 participants.

Study design
This is a Phase 1, open-label study, meaning both you and your doctors will know you are receiving JANX014. The study plans to enroll 43 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to 2 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07545811

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
Janux Therapeutics
~43 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:JANX014

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Dose Limiting Toxicities (DLTs)
Measured over 2 years
+1 more outcome measured

Conditions

Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Castration-resistant Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

4 sites across 4 states
Missouri1
South Carolina1
Tennessee1
Texas1

Who to contact

Janux Therapeutics, MD
[email protected]
+1 858-206-8471
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male ≥18 years of age at the time of signing informed consent
Histologically or cytologically confirmed adenocarcinoma of the prostate
For Dose Escalation: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible.
Adequate organ function
For Dose Expansion Part: Have received ≤ 2 anti-androgen therapies in either the HSPC or CRPC setting and no more than 1 prior taxane regimen in the HSPC setting. Participants who have actively refused a taxane regimen or are medically unsuitable to receive taxane are eligible.

Exclusion

Prior solid organ transplant
Prior treatment with any CAR-T cell therapy, approved or investigational T-cell engager therapy, and prior receipt of radioligand therapy
Clinically significant cardiovascular disease

What this trial measures

  • Incidence of Dose Limiting Toxicities (DLTs)2 years
  • Incidence of adverse events (AE) and Serious Adverse Events (SAE)2 years